FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:1417-1418 May 2, 2002 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: In 1992, we reported the results of the prospective, randomized Cancer and Leukemia Group B trial in patients with newly diagnosed, advanced-stage Hodgkin's disease. The study compared three regimens: MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) for 6 to 8 months, the standard treatment at that time; ABVD, a nonalkylating-agent–containing regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine) for 6 to 8 months; and MOPP alternating with ABVD for 12 months.¹

Radiation therapy was not administered. ABVD therapy alone for 6 to 8 months resulted in a rate of failure-free survival similar to the rate with a 12-month regimen of . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Lister, T. A. (2008). Treatment of Stage IIIa Hodgkin's Disease: Long Follow-Up Perspective. JCO 26: 5144-5146 [Full Text]  
• Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., Loft, A., Di Raimondo, F., D'Amore, F., Biggi, A., Vitolo, U., Stelitano, C., Sancetta, R., Trentin, L., Luminari, S., Iannitto, E., Viviani, S., Pierri, I., Levis, A. (2007). Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study. JCO 25: 3746-3752 [Abstract] [Full Text]  
• Brusamolino, E., Carella, A. M. (2007). Treatment of refractory and relapsed Hodgkin's lymphoma: facts and perspectives. haematol 92: 6-10 [Full Text]  
• Horning, S. J. (2007). Risk, Cure and Complications in Advanced Hodgkin Disease. ASH Education Book 2007: 197-203 [Abstract] [Full Text]  
• Guadagnolo, B. A., Punglia, R. S., Kuntz, K. M., Mauch, P. M., Ng, A. K. (2006). Cost-Effectiveness Analysis of Computerized Tomography in the Routine Follow-Up of Patients After Primary Treatment for Hodgkin's Disease. JCO 24: 4116-4122 [Abstract] [Full Text]  
• Sanchez-Aguilera, A., Montalban, C., de la Cueva, P., Sanchez-Verde, L., Morente, M. M., Garcia-Cosio, M., Garcia-Larana, J., Bellas, C., Provencio, M., Romagosa, V., de Sevilla, A. F., Menarguez, J., Sabin, P., Mestre, M. J., Mendez, M., Fresno, M. F., Nicolas, C., Piris, M. A., Garcia, J. F., for the Spanish Hodgkin Lymphoma Study Group, (2006). Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 108: 662-668 [Abstract] [Full Text]  
• Ferme, C., Mounier, N., Casasnovas, O., Brice, P., Divine, M., Sonet, A., Bouafia, F., Bastard-Stamatoullas, A., Bordessoule, D., Voillat, L., Reman, O., Blanc, M., Gisselbrecht, C., for the Groupe d'Etude des Lymphomes de l'Adulte, (2006). Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 107: 4636-4642 [Abstract] [Full Text]  
• Gobbi, P. G., Broglia, C., Levis, A., La Sala, A., Valentino, F., Chisesi, T., Sacchi, S., Corbella, F., Cavanna, L., Iannitto, E., Pavone, V., Molica, S., Corazza, G. R., Federico, M. (2006). MOPPEBVCAD Chemotherapy with Limited and Conditioned Radiotherapy in Advanced Hodgkin's Lymphoma: 10-Year Results, Late Toxicity, and Second Tumors. Clin. Cancer Res. 12: 529-535 [Abstract] [Full Text]  
• Rueda Dominguez, A., Marquez, A., Guma, J., Llanos, M., Herrero, J., de las Nieves, M. A., Miramon, J., Alba, E. (2004). Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol 15: 1798-1804 [Abstract] [Full Text]  
• Kumar, R., Xiu, Y., Potenta, S., Mavi, A., Zhuang, H., Yu, J. Q., Dhurairaj, T., Dadparvar, S., Alavi, A. (2004). 18F-FDG PET for Evaluation of the Treatment Response in Patients with Gastrointestinal Tract Lymphomas. JNM 45: 1796-1803 [Abstract] [Full Text]  
• Diehl, V. (2004). Chemotherapy or Combined Modality Treatment: The Optimal Treatment for Hodgkin's Disease. JCO 22: 15-18 [Full Text]  
• Engert, A., Schiller, P., Josting, A., Herrmann, R., Koch, P., Sieber, M., Boissevain, F., de Wit, M., Mezger, J., Duhmke, E., Willich, N., Muller, R.-P., Schmidt, B. F., Renner, H., Muller-Hermelink, H. K., Pfistner, B., Wolf, J., Hasenclever, D., Loffler, M., Diehl, V. (2003). Involved-Field Radiotherapy Is Equally Effective and Less Toxic Compared With Extended-Field Radiotherapy After Four Cycles of Chemotherapy in Patients With Early-Stage Unfavorable Hodgkin's Lymphoma: Results of the HD8 Trial of the German Hodgkin's Lymphoma Study Group. JCO 21: 3601-3608 [Abstract] [Full Text]  
• Aleman, B. M.P., Raemaekers, J. M.M., Tirelli, U., Bortolus, R., van 't Veer, M. B., Lybeert, M. L.M., Keuning, J. J., Carde, P., Girinsky, T., van der Maazen, R. W.M., Tomsic, R., Vovk, M., van Hoof, A., Demeestere, G., Lugtenburg, P. J., Thomas, J., Schroyens, W., De Boeck, K., Baars, J. W., Kluin-Nelemans, J. C., Carrie, C., Aoudjhane, M., Bron, D., Eghbali, H., Smit, W. G.J.M., Meerwaldt, J. H., Hagenbeek, A., Pinna, A., Henry-Amar, M., the European Organization for Research and Treatme, (2003). Involved-Field Radiotherapy for Advanced Hodgkin's Lymphoma. NEJM 348: 2396-2406 [Abstract] [Full Text]  
• Diehl, V. (2003). Advanced Hodgkin's Disease: ABVD Is Better, Yet Is Not Good Enough!. JCO 21: 583-585 [Full Text]